← Back to patent-cliff list
Aztreonam lysine
Tier C — Watch / tradeAztreonam lysine
Gilead Inc
Originator
2009
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PBPs
Brand：Cayston
Indications (approved)：Cystic fibrosis
Regional status
US
Discontinued
2005-02-01
EU
Approved
2009-09-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Aztreonam lysine?
Approved indications include: Cystic fibrosis.
When does the Aztreonam lysine patent expire?
No public expiry year is available for Aztreonam lysine yet; this page updates once verified.
How do I get a quote for Aztreonam lysine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29